ReNeuron’s long term data from its Phase II stroke trial confirming the positive results seen after three months is very encouraging. The results highlight the potential of the group’s CTX cell therapy to improve long term outcomes in disability, dependence and motor function in disabled stroke patients. Further detail will be announced at a medical conference in due course. ReNeuron plans to commence a pivotal trial in the US in early 2018 with data now expected H2 2019 (from early 2020) as it ....
31 Oct 2017
N+1 Singer - ReNeuron Group - Positive long term data in Phase II stroke trial
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - ReNeuron Group - Positive long term data in Phase II stroke trial
ReNeuron Group plc (RENE:LON) | 0 0 0.0% | Mkt Cap: 1.74m
- Published:
31 Oct 2017 -
Author:
Sheena Berry -
Pages:
3
ReNeuron’s long term data from its Phase II stroke trial confirming the positive results seen after three months is very encouraging. The results highlight the potential of the group’s CTX cell therapy to improve long term outcomes in disability, dependence and motor function in disabled stroke patients. Further detail will be announced at a medical conference in due course. ReNeuron plans to commence a pivotal trial in the US in early 2018 with data now expected H2 2019 (from early 2020) as it ....